Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

71 results
Display

Analysis of Tau Protein Expression in Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Different Molecular Subtypes of Breast Cancer

Lei C, Yang C, Xia B, Ji F, Zhang Y, Gao H, Xiong Q, Lin Y, Zhuang X, Zhang L, Zhu T, Cheng M, Yang M, Wang K

PURPOSE: Tau is a microtubule-associated protein that can be found in both normal and abnormal breast cells. Whether the expression of Tau protein can predict the response to neoadjuvant chemotherapy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Downregulation of N-myc and STAT Interactor Protein Predicts Aggressive Tumor Behavior and Poor Prognosis in Invasive Ductal Carcinoma

Choi JE, Hyun CL, Jin MS, Lee KM, Moon JH, Ryu HS

PURPOSE: We investigated the expression of the N-myc and STAT interactor (NMI) protein in invasive ductal carcinoma tissue and estimated its clinicopathologic significance as a prognostic factor. The expression levels...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Measuring Tumor Extent Based on Subtypes Using Magnetic Resonance Imaging: Radiologic-Pathologic Discordance and High Positive Margin Rates in Breast Cancer

Bae SJ, Ahn SG, Yoon CI, Yang BS, Lee HW, Son EJ, Jeong J

PURPOSE: We evaluated the clinical value of breast magnetic resonance imaging (MRI) in patients who underwent breast-conserving surgery (BCS). The degree of correlation between pathology size and MRI or ultrasonography...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Potential Benefits of Neoadjuvant Chemotherapy in Clinically Node-Positive Luminal Subtype⁻ Breast Cancer

Kim HS, Yoo TK, Park WC, Chae BJ

PURPOSE: Neoadjuvant chemotherapy (NAC) is less effective for luminal breast cancer because luminal breast cancer has a lower rate of pathological complete response (pCR) after NAC than human epidermal growth...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer

Nakhjavani M, Hardingham JE, Palethorpe HM, Price TJ, Townsend A

Breast cancer (BC) is still the most common cancer among women worldwide. Amongst the subtypes of BC, triple negative breast cancer (TNBC) is characterized by deficient expression of estrogen, progesterone,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Organ-Specific Recurrence or Metastatic Pattern of Breast Cancer according to Biological Subtypes and Clinical Characteristics

Kim J, Lee Y, Yoo T, Kim J, Hyun J, Park I, Cho H, Yang K, Bae B, Kim K, Park K, Gwak G

PURPOSE: We aimed to investigate organ-specific recurrence or the metastatic pattern of breast cancer according to biological subtypes and clinical characteristics. METHODS: We retrospectively analyzed the medical records of 168 patients...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Treatment Outcomes of Weakly Positive Hormone Receptor Breast Cancer and Triple-Negative Breast Cancer

Yoon MR, Rhu JY, Song BJ, Chae BJ, Yoo TK

PURPOSE: In breast cancer, response to endocrine therapy depends on estrogen receptor and progesterone receptor status. However, poor prognosis is conferred on patients with hormone receptor (HR)-positive breast cancer. We...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
High Survivin and Low Zinc Finger of the Cerebellum 1 Expression Indicates Poor Prognosis in Triple-negative Breast Carcinoma

Shi CT, Ma J, Shi QF, Zhang Y, Wang HN

PURPOSE: Triple-negative breast carcinoma (TNBC) is accompanied with high risk of metastasis and recurrence. The present study aimed to explore the clinicopathological and prognostic roles of putative tumor-related genes in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Association between p53 Expression and Amount of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer

Lee M, Park IA, Heo SH, Kim YA, Gong G, Lee HJ

BACKGROUND: Most triple-negative breast cancers (TNBCs) have a high histologic grade, are associated with high endoplasmic stress, and possess a high frequency of TP53 mutations. TP53 missense mutations lead to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance

Kim HK, Park KH, Kim Y, Park SE, Lee HS, Lim SW, Cho JH, Kim JY, Lee JE, Ahn JS, Im YH, Yu JH, Park YH

PURPOSE: We aimed to analyze the discordance between immunohistochemistry (IHC)-based surrogate subtyping and PAM50 intrinsic subtypes and to assess overall survival (OS) according to discordance. MATERIALS AND METHODS: A total of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer

Lee J, Kim DM, Lee A

PURPOSE: Tumor-infiltrating lymphocyte (TIL), programmed death-ligand 1 (PD-L1) expression and neutrophil-to-lymphocyte ratio (NLR) is associated to immunogenicity and prognosis of breast cancer. We analyzed baseline NLR, changes of NLR, TIL,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Identification of ERBB Pathway-Activated Cells in Triple-Negative Breast Cancer

Cho SY

Intratumor heterogeneity within a single tumor mass is one of the hallmarks of malignancy and has been reported in various tumor types. The molecular characterization of intratumor heterogeneity in breast...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin

Abdel Azim H, Kassem L, Shohdy KS, Eshaak B, Anis SE, Kamal NS

The luteinizing hormone-releasing hormone/androgen receptor (LHRH/AR) pathway is a promising treatment target in a subgroup of female patients with triple-negative breast cancer (TNBC). However, very little is known about the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Salivary Duct Cancer Metastasis Mimicking Primary Breast Cancer: A Case Report and Review

Alzuhair A, Gong G, Shin HJ, Lee JW, Lee SB, Kim J, Ko BS, Son BH, Ahn SH, Chung IY

Secondary breast malignancy is a rare occurrence, accounting for less than 2% of all breast malignancies. Salivary duct carcinoma (SDC) metastasizing to the breast has not been reported previously. This...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Notch1 in Tumor Microvascular Endothelial Cells and Tumoral miR-34a as Prognostic Markers in Locally Advanced Triple-Negative Breast Cancer

Kim D, Lee J, Kang J, Kim SH, Yoo TK, Oh S, Lee A

PURPOSE: Triple-negative breast cancer (TNBC) is associated with poor prognosis with limited treatment options. Angiogenesis is known to be involved in the progression of TNBC, and targeting this pathway results...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Genistein Inhibits Proliferation of BRCA1 Mutated Breast Cancer Cells: The GPR30-Akt Axis as a Potential Target

Kim GY, Suh J, Jang JH, Kim DH, Park OJ, Park SK, Surh YJ

BACKGROUND: BRCA1 mutated breast cancer cells exhibit the elevated cell proliferation and the higher metastatic potential. G protein-coupled receptor 30 (GPR30) has been shown to regulate growth of hormonally responsive...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
p90RSK Activation Promotes Epithelial-Mesenchymal Transition in Cisplatin-Treated Triple-Negative Breast Cancer Cells

Jin Y, Heo KS

p90 ribosomal S6 kinase (p90RSK), one of the downstream effectors in ERK1/2 pathways, shows high expression in human breast cancer tissues. However, its role in breast cancer development and drug...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Expression of Immunoproteasome Subunit LMP7 in Breast Cancer and Its Association with Immune-Related Markers

Lee M, Song IH, Heo SH, Kim YA, Park IA, Bang WS, Park HS, Gong G, Lee HJ

PURPOSE: In the presence of interferon, proteasome subunits are replaced by their inducible counterparts to form an immunoproteasome (IP) plays a key role in generation of antigenic peptides presented by...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)

Park IH, Im SA, Jung KH, Sohn JH, Park YH, Lee KS, Sim SH, Park KH, Kim JH, Nam BH, Kim HJ, Kim TY, Lee KH, Kim SB, Ahn JH, Lee S, Ro J

PURPOSE: We investigated whether irinotecan plus capecitabine improved progression-free survival (PFS) compared with capecitabine alone in patients with human epidermal growth factor 2 (HER2) negative and anthracycline and taxane pretreated...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hsa-miRNA-143-3p Reverses Multidrug Resistance of Triple-Negative Breast Cancer by Inhibiting the Expression of Its Target Protein Cytokine-Induced Apoptosis Inhibitor 1 In Vivo

Deng YW, Hao WJ, Li YW, Li YX, Zhao BC, Lu D

PURPOSE: Multidrug resistance (MDR) remains a major obstacle in the treatment of triple-negative breast cancer (TNBC) with conventional chemotherapeutic agents. A previous study demonstrated that hsa-miRNA-143-3p plays a vital role...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr